Last reviewed · How we verify
NCT03257150
A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer
Completed
NA
Last updated 11 August 2022
What this trial tests
NA trial testing Irreversible Electroporation in Pancreatic Ductal Adenocarcinoma in 12 participants. Completed in 14 July 2022.
Timeline
22 September 2017
Primary endpoint
14 July 2022
14 July 2022
14 July 2022
Quick facts
| Lead sponsor | University Health Network, Toronto |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 22 September 2017 |
| Primary completion | 14 July 2022 |
| Estimated completion | 14 July 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Irreversible Electroporation
- NanoKnife System
Conditions studied
- Pancreatic Ductal Adenocarcinoma — all drugs for Pancreatic Ductal Adenocarcinoma →
Sponsor
University Health Network, Toronto
Who can join
18 and older, any sex, with Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This I/II study will evaluate to see how safe and useful irreversible electroporation (also called NanoKnife) is in patients with locally advanced pancreatic cancer.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies.
Bazeed AY, Day CM, Garg S. · · 2022 · cited 42× · PMID 36077794 · DOI 10.3390/cancers14174257 -
Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer.
Lafranceschina S, Brunetti O, Delvecchio A, Conticchio M, et al · · 2019 · cited 29× · PMID 31684186 · DOI 10.3390/cancers11111718 -
Advances in the management of pancreatic ductal adenocarcinoma.
O'Kane GM, Ladak F, Gallinger S. · · 2021 · cited 18× · PMID 34099468 · DOI 10.1503/cmaj.201450 -
Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma.
Lambin T, Lafon C, Drainville RA, Pioche M, et al · · 2022 · cited 13× · PMID 35645539 · DOI 10.3748/wjg.v28.i13.1288 -
Minimally invasive image-guided therapy of primary and metastatic pancreatic cancer.
Bibok A, Kim DW, Malafa M, Kis B. · · 2021 · cited 9× · PMID 34366607 · DOI 10.3748/wjg.v27.i27.4322 -
Are Aspects of Integrative Concepts Helpful to Improve Pancreatic Cancer Therapy?
Oei SL, Schad F. · · 2023 · cited 5× · PMID 36831465 · DOI 10.3390/cancers15041116 -
Avancées dans la prise en charge de l’adénocarcinome canalaire pancréatique.
O'Kane GM, Ladak F, Gallinger S. · · 2021 · PMID 34462299 · DOI 10.1503/cmaj.201450-f
Verify or expand the search:
- PubMed search for NCT03257150
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Irreversible Electroporation
Trials testing the same drug.
- NCT06378047 — Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer · Phase 1 · completed
- NCT04972097 — Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue · NA · completed
- NCT03080974 — Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT03008343 — Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer · Phase 1, PHASE2 · completed
Other recruiting trials for Pancreatic Ductal Adenocarcinoma
Currently open trials in the same condition.
- NCT07324096 — A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Deve · NA · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07328607 — Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy · NA · recruiting
- NCT07232810 — Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer · NA · recruiting
- NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
Other University Health Network, Toronto trials
Trials by the same sponsor.
- NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
- NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
- NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
- NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
- NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03257150 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
- Last refreshed: 11 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03257150.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing